Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter double-blind placebo-controlled parallel-group study of MK-0974 for acute migraine
2007-002667-28Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telcagepant in migraine (3 arms), sponsored by Merck & Co. Primary endpoints: Sustained pain freedom 2–24 hours post-dose (first attack), Sustained pain freedom 2–48 hours post-dose (first attack) and 3 more. Started Apr 2008; status: completed.
02
Drugs
telcagepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2007-002667-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002667-28.